We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Catalent, a provider of improved treatments for patients worldwide, has announced the expansion of services and capabilities at its Shiga facility in Japan. The facility now offers storage,
ANGLE, a liquid biopsy firm, announced that Artios Pharma (Artios), its first client for assay development, has inked a new contract to use two DNA Damage Response assays
Novo Nordisk and Life Edit Therapeutics, a subsidiary of ElevateBio that specialises in innovative gene editing technologies and treatments, have recently joined forces through a collaborative research and
ReNAgade Therapeutics, a company harnessing the boundless potential of RNA medicines to treat diseases, has recently disclosed a Series A funding round of $300 million. This significant investment
Odyssey Therapeutics has secured $168m in a Series B financing round, led by General Catalyst, with participation from all existing investors and new leading institutional investors and mutual
Everest Medicines has signed an agreement to transfer the exclusive rights to develop and commercialise Trodelvy (sacituzumab govitecan) in key Asian markets to Gilead Sciences. As agreed, Everest
Novartis has announced that the Phase III CANOPY-A study, that assessed the efficacy of canakinumab in non-small cell lung cancer (NSCLC) patients, has failed to reach its primary
Gemini Therapeutics, a clinical-stage precision medicine company, has agreed to merge with Disc Medicine in an all-stock transaction to create a clinical-stage biopharmaceutical firm. To support the deal,
Biotechnology firm Aro Biotherapeutics has secured the US Food and Drug Administration (FDA) Orphan Drug Designation for its ABX1100 to treat Pompe disease. ABX1100 is an investigational Centyrin-small
BridgeBio Pharma has signed an exclusive licence deal with Bristol Myers Squibb (BMS) to develop and market BridgeBio’s BBP-398 in oncology. BBP-398, an inhibitor of SHP2, was founded through